Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Pyme británica ofrece una nueva molécula pequeña para el tratamiento de la fibrosis causada por la enfermedad intestinal inflamatoria

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20180413002
Publicado:
14/05/2018
Caducidad:
15/05/2019
Resumen:
Una pyme británica ha desarrollado una nueva molécula pequeña capaz de prevenir y revertir la fibrosis causada por la enfermedad intestinal inflamatoria. Esta potente actividad se combina con un buen perfil de seguridad sin efectos secundarios demostrados en modelos animales. La molécula tiene actividad contra las proteínas ROCK 1 y 2 (Rho-associated coiled-coil-containing protein kinase), implicadas en numerosos aspectos del proceso de fibrosis. La empresa busca compañías farmacéuticas interesadas en continuar con el desarrollo y comercializar la tecnología bajo acuerdos de licencia o cooperación técnica.

Details

Tittle:
UK-based SME offer novel small molecule for treatment of fibrosis caused by inflammatory bowel disease
Summary:
A UK-based SME has developed a novel small molecule shown to be able to prevent and reverse fibrosis caused by inflammatory bowel disease.This potent activity is combined with a good safety profile with no adverse effects shown in animal models tested. The SME is offering this small molecule to other pharmaceutical companies for further development and commercialisation. It is expected that the partnership will take the form of a licensing agreement or a technical cooperation
Description:
Patients with inflammatory bowel disease (IBD) are at high risk of developing fibrosis that can cause narrowing and obstruction of the bowel. This occurs in 30-40% of patients within 10 years of their diagnosis and of these 80% require surgery but recurrence occurs in 70% of cases. Methods of preventing and treating this fibrosis are therefore needed.

A UK-based SME has developed a novel small molecule that has activity against ROCK 1 and 2 (Rho-associated coiled-coil-containing protein kinase), which are proteins involved in multiple aspects of the process of fibrosis. This novel small molecule has been shown to be potent and selective against its targets, with enantiomers having similar biological properties. This activity has been shown to prevent and even reverse fibrotic phenotypes in cell culture systems and mouse models. This is combined with a good safety profile with no adverse effects seen in animal models.

The SME is offering this novel small molecule to other companies operating in the pharmaceutical space. In particular those with an interest in fibrosis and fibrotic diseases. The molecule will be provided for further development and commercialisation with the partnership envisaged as a licensing agreement or a technical cooperation depending on circumstances.
Advantages and Innovations:
The SMEs novel small molecule has the following advantages:

Potent and selective activity against ROCK 1/2 - efficacy is in the low nano-molar range.

Prevents and even reverses fibrotic changes, demonstrated both in vitro and in vivo.

Good safety profile in animal models.

Limited systemic exposure even at doses significantly above therapeutic levels with significant drug concentrations remaining in colon tissue 24 hours after oral dosing.
Stage of Development:
Under development/lab tested
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
The SME is looking to partner with other companies in the pharmaceutical sector and in particular those with interests in fibrosis and fibrotic diseases.

The SME will provide the novel small molecule to a partner for further development and ultimately commercialisation. It is expected that the partnership will take the form of a licensing agreement, although technical cooperations will be considered if the situation warrants it.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos